Haemorrhagic colitis due to Escherichia coli O103:H2 associated with infliximab therapy in a patient with rheumatoid arthritis.
Kirchgatterer
A
A
Weber
T
T
Hinterreiter
M
M
Knoflach
P
P
Allerberger
F
F
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D003093:Colitis, Ulcerative / Q000209:etiology* / Q000382:microbiology / Q000473:pathology; D004926:Escherichia coli / Q000302:isolation & purification* / Q000472:pathogenicity / Q000502:physiology; D004927:Escherichia coli Infections / Q000150:complications* / Q000473:pathology; D005260:Female; D006801:Humans; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab